Christin A. Knowlton

Christin A. Knowlton, MD, MA serves as Associate Professor of Therapeutic Radiology at Yale School of Medicine, where she holds dual leadership roles as Vice Chair for Accreditation in Therapeutic Radiology and Medical Director of Smilow Cancer Hospital Care Center-Hamden. Her clinical practice focuses on delivering high-quality, patient-centered radiation oncology services with specialization in breast cancer, lung cancer, bone metastases, and thymoma treatments.

Dr. Knowlton's educational background includes a BA from Oberlin College (1994), MA from New York University (1998), MD from SUNY at Stonybrook (2006), and residency training at Hahnemann University Hospital/Drexel University College of Medicine (2011). Her research program centers on optimizing radiation therapy protocols, with particular emphasis on hypofractionation techniques, stereotactic body radiation therapy (SBRT), and management of radiation-related toxicities including pneumonitis and esophagitis.

Analysis of her 15 most recent publications reveals a consistent research trajectory focused on improving outcomes in thoracic and breast radiation oncology through dose optimization, toxicity prediction modeling, and innovative treatment approaches for oligometastatic disease. Her work frequently addresses the balance between therapeutic efficacy and radiation-induced complications, with growing emphasis on molecular risk assessment and personalized treatment planning.

• Smilow Luminary Award of Excellence in Patient Care (2019)
• National Comprehensive Cancer Network (NCCN) Fellows Recognition Program

As a clinician-educator, Dr. Knowlton emphasizes the importance of patient communication and multidisciplinary teamwork, collaborating closely with nursing, physics, dosimetry, and therapy staff to deliver comprehensive cancer care. Her leadership in accreditation reflects her commitment to maintaining the highest standards in radiation oncology practice and education. Dr. Knowlton's clinical trial involvement, including the DD3 trial of dose-deescalated SBRT for centrally located lung cancer, demonstrates her active contribution to advancing evidence-based radiation oncology practice.